



30 April 2019

Proteome Sciences plc
(“Proteome Sciences” or the “Company”)

Annual General Meeting (AGM) Statement and Q1 Trading Update

At the Company’s AGM being held today at 2.30 pm the Chairman, Christopher Pearce, will make the following statement:

“As indicated in our recent results, we remain optimistic about the future, with the near-term availability of higher-plex TMT[®] set to add significant value to this asset, and the utility of quantitative proteomics increasing in response to diagnostic advances and disruptive technologies. We are pleased to report a good first quarter, with further growth in sales and royalties from TMT[®] and an improving services business continuing the trend in orders and revenues established during the latter part of 2018.”

For further information:

Proteome Sciences plc

Dr Jeremy Haigh, Chief Executive Officer
Dr Ian Pike, Chief Scientific Officer
Richard Dennis, Chief Commercial Officer

Tel: +44 (0)20 7043 2116

Allenby Capital Limited (AIM Nominated Adviser & Broker)

John Depasquale / Jeremy Porter

Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant[®] and TMT[®]MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator[™] provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany.